146 related articles for article (PubMed ID: 19013564)
1. Depot medroxyprogesterone acetate use after peak bone mass is associated with increased bone turnover but no decrease in bone mineral density.
Walsh JS; Eastell R; Peel NF
Fertil Steril; 2010 Feb; 93(3):697-701. PubMed ID: 19013564
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate.
Clark MK; Sowers MR; Nichols S; Levy B
Fertil Steril; 2004 Dec; 82(6):1580-6. PubMed ID: 15589863
[TBL] [Abstract][Full Text] [Related]
3. Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling.
Shaarawy M; El-Mallah SY; Seoudi S; Hassan M; Mohsen IA
Contraception; 2006 Oct; 74(4):297-302. PubMed ID: 16982229
[TBL] [Abstract][Full Text] [Related]
4. The effect of depot medroxyprogesterone acetate (DMPA) on bone mineral density (BMD) and evaluating changes in BMD after discontinuation of DMPA in Chinese women of reproductive age.
Gai L; Zhang J; Zhang H; Gai P; Zhou L; Liu Y
Contraception; 2011 Mar; 83(3):218-22. PubMed ID: 21310282
[TBL] [Abstract][Full Text] [Related]
5. Bone mineral density and depot medroxyprogesterone acetate.
Albertazzi P; Bottazzi M; Steel SA
Contraception; 2006 Jun; 73(6):577-83. PubMed ID: 16730487
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate.
Clark MK; Sowers M; Levy B; Nichols S
Fertil Steril; 2006 Nov; 86(5):1466-74. PubMed ID: 16996507
[TBL] [Abstract][Full Text] [Related]
7. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception.
Scholes D; LaCroix AZ; Ichikawa LE; Barlow WE; Ott SM
Arch Pediatr Adolesc Med; 2005 Feb; 159(2):139-44. PubMed ID: 15699307
[TBL] [Abstract][Full Text] [Related]
8. A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate.
Viola AS; Castro S; Bahamondes MV; Fernandes A; Viola CF; Bahamondes L
Contraception; 2011 Nov; 84(5):e31-7. PubMed ID: 22018135
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density in women aged 40-49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception.
Beksinska ME; Smit JA; Kleinschmidt I; Farley TM; Mbatha F
Contraception; 2005 Mar; 71(3):170-5. PubMed ID: 15722065
[TBL] [Abstract][Full Text] [Related]
10. Bone mineral density in women using depot medroxyprogesterone acetate (DMPA) for at least 2 years compared to a control group: a cross sectional study.
Pongsatha S; Ekmahachai M; Chaovisitsaree S; Suntornlimsiri N; Morakote N
J Med Assoc Thai; 2009 Oct; 92(10):1263-7. PubMed ID: 19845231
[TBL] [Abstract][Full Text] [Related]
11. Bone mineral density in adolescent females using depot medroxyprogesterone acetate.
Lara-Torre E; Edwards CP; Perlman S; Hertweck SP
J Pediatr Adolesc Gynecol; 2004 Feb; 17(1):17-21. PubMed ID: 15010034
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of Low Bone Mass and Osteoporosis in Long-Term Users of the Injectable Contraceptive Depot Medroxyprogesterone Acetate.
Modesto W; Bahamondes MV; Bahamondes L
J Womens Health (Larchmt); 2015 Aug; 24(8):636-40. PubMed ID: 26098552
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
Kaunitz AM; Darney PD; Ross D; Wolter KD; Speroff L
Contraception; 2009 Jul; 80(1):7-17. PubMed ID: 19501210
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal study of depot medroxyprogesterone acetate (Depo-Provera) effects on bone health in adolescents: study design, population characteristics and baseline bone mineral density.
Johnson CC; Burkman RT; Gold MA; Brown RT; Harel Z; Bruner A; Stager M; Bachrach LK; Hertweck SP; Nelson AL; Nelson DA; Coupey SM; McLeod A; Bone HG
Contraception; 2008 Apr; 77(4):239-48. PubMed ID: 18342646
[TBL] [Abstract][Full Text] [Related]
15. Biopsychosocial variables associated with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate in adolescents: adolescents who lost 5% or more from baseline vs. those who lost less than 5%.
Harel Z; Wolter K; Gold MA; Cromer B; Stager M; Johnson CC; Brown R; Bruner A; Coupey S; Hertweck P; Bone H; Burkman R; Nelson A; Marshall S; Bachrach LK
Contraception; 2010 Dec; 82(6):503-12. PubMed ID: 21074012
[TBL] [Abstract][Full Text] [Related]
16. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.
Kaunitz AM
Int J Fertil Womens Med; 1998; 43(2):73-83. PubMed ID: 9609206
[TBL] [Abstract][Full Text] [Related]
17. Bone density in women receiving depot medroxyprogesterone acetate for contraception.
Cundy T; Evans M; Roberts H; Wattie D; Ames R; Reid IR
BMJ; 1991 Jul; 303(6793):13-6. PubMed ID: 1830502
[TBL] [Abstract][Full Text] [Related]
18. Bone density in long term users of depot medroxyprogesterone acetate.
Gbolade B; Ellis S; Murby B; Randall S; Kirkman R
Br J Obstet Gynaecol; 1998 Jul; 105(7):790-4. PubMed ID: 9692421
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation.
Kaunitz AM; Miller PD; Rice VM; Ross D; McClung MR
Contraception; 2006 Aug; 74(2):90-9. PubMed ID: 16860045
[TBL] [Abstract][Full Text] [Related]
20. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women.
Scholes D; LaCroix AZ; Ichikawa LE; Barlow WE; Ott SM
Contraception; 2004 Feb; 69(2):99-104. PubMed ID: 14759613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
